Relevant bibliographies by topics / Human papillomavirus

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Human papillomavirus'

Author: Grafiati
Published: 4 June 2021
Last updated: 10 March 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Human papillomavirus.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Human papillomavirus"

1

Tong, Yan, Philip Tonui, Aaron Ermel, Omenge Orang’o, Nelson Wong, Maina Titus, Stephen Kiptoo, Kapten Muthoka, Patrick J. Loehrer, and Darron R. Brown. "Persistence of oncogenic and non-oncogenic human papillomavirus is associated with human immunodeficiency virus infection in Kenyan women." SAGE Open Medicine 8 (January 2020): 205031212094513. http://dx.doi.org/10.1177/2050312120945138.

Full text
Abstract:
Objectives: Cervical cancer is caused by persistent infection with oncogenic, or “high-risk” types of human papillomaviruses, and is the most common malignancy in Kenyan women. A longitudinal study was initiated to investigate factors associated with persistent human papillomavirus detection among HIV-infected and HIV-uninfected Kenyan women without evidence of cervical dysplasia. Methods: Demographic/behavioral data and cervical swabs were collected from HIV-uninfected women (n = 82) and HIV-infected women (n = 101) at enrollment and annually for 2 years. Human papillomavirus typing was performed on swabs (Roche Linear Array). Logistic regression models of human papillomavirus persistence were adjusted for demographic and behavioral characteristics. Results: HIV-infected women were older and less likely to be married and to own a home and had more lifetime sexual partners than HIV-uninfected women. All HIV-infected women were receiving anti-retroviral therapy at enrollment and had satisfactory CD4 cell counts and HIV viral loads. One- and two-year persistent human papillomavirus detection was significantly associated with HIV infection for any human papillomavirus, high-risk human papillomavirus, International Agency for the Research on Cancer-classified high-risk human papillomavirus, and non-oncogenic “low-risk” human papillomavirus. Conclusion: Persistent detection of oncogenic and non-oncogenic human papillomavirus was strongly associated with HIV infection in Kenyan women with re-constituted immune systems based on satisfactory CD4 cell counts. In addition to HIV infection, factors associated with an increased risk of human papillomavirus persistence included a higher number of lifetime sex partners. Factors associated with decreased risk of human papillomavirus persistence included older age and being married. Further studies are needed to identify the immunological defects in HIV-infected women that allow human papillomavirus persistence, even in women receiving effective anti-retroviral therapy. Further studies are also needed to determine the significance of low-risk human papillomavirus persistence in HIV-infected women.
APA, Harvard, Vancouver, ISO, and other styles
2

Strauss, Melvin, and A. Bennett Jenson. "Human Papillomavirus in Various Lesions of the Head and Neck." Otolaryngology–Head and Neck Surgery 93, no. 3 (June 1985): 342–46. http://dx.doi.org/10.1177/019459988509300310.

Full text
Abstract:
The association of human papillomavirus with benign and malignant epithelial lesions of the head and neck has been studied by a peroxidase-antiperoxidase technique having immunospecificity against genus-specific structural antigens of the papillomaviruses. More than 360 specimen blocks from 144 patients were evaluated. There was evidence of human papillomavirus antigen in three out of eight patients with childhood-onset laryngeal papillomas (37.5%) and in four out of eight patients with adult-onset papillomas (50%). A patient with an unusual flat, wartlike lesion appearing as an oral cavity leukoplakia had detectable papillomavirus antigen in it. None of the 13 cases of inverting papilloma or any of the malignant lesions studied showed evidence for the presence of papillomavirus antigen. There is currently only suggestive evidence for the oncogenic potential of human papillomavirus in the head and neck.
APA, Harvard, Vancouver, ISO, and other styles
3

Buck, Christopher B., Diana V. Pastrana, Douglas R. Lowy, and John T. Schiller. "Efficient Intracellular Assembly of Papillomaviral Vectors." Journal of Virology 78, no. 2 (January 15, 2004): 751–57. http://dx.doi.org/10.1128/jvi.78.2.751-757.2004.

Full text
Abstract:
ABSTRACT Although the papillomavirus structural proteins, L1 and L2, can spontaneously coassemble to form virus-like particles, currently available methods for production of L1/L2 particles capable of transducing reporter plasmids into mammalian cells are technically demanding and relatively low-yield. In this report, we describe a simple 293 cell transfection method for efficient intracellular production of papillomaviral-based gene transfer vectors carrying reporter plasmids. Using bovine papillomavirus type 1 (BPV1) and human papillomavirus type 16 as model papillomaviruses, we have developed a system for producing papillomaviral vector stocks with titers of several billion transducing units per milliliter. Production of these vectors requires both L1 and L2, and transduction can be prevented by papillomavirus-neutralizing antibodies. The stocks can be purified by an iodixanol (OptiPrep) gradient centrifugation procedure that is substantially more effective than standard cesium chloride gradient purification. Although earlier data had suggested a potential role for the viral early protein E2, we found that E2 protein expression did not enhance the intracellular production of BPV1 vectors. It was also possible to encapsidate reporter plasmids devoid of BPV1 DNA sequences. BPV1 vector production efficiency was significantly influenced by the size of the target plasmid being packaged. Use of 6-kb target plasmids resulted in BPV1 vector yields that were higher than those with target plasmids closer to the native 7.9-kb size of papillomavirus genomes. The results suggest that the intracellular assembly of papillomavirus structural proteins around heterologous reporter plasmids is surprisingly promiscuous and may be driven primarily by a size discrimination mechanism.
APA, Harvard, Vancouver, ISO, and other styles
4

Awua, Adolf K., Alberto Severini, Edwin K. Wiredu, Edwin A. Afari, Vanessa A. Zubach, and Richard M. K. Adanu. "Self-Collected Specimens Revealed a Higher Vaccine- and Non-Vaccine-Type Human Papillomavirus Prevalences in a Cross-Sectional Study in Akuse." Advances in Preventive Medicine 2020 (January 22, 2020): 1–13. http://dx.doi.org/10.1155/2020/8343169.

Full text
Abstract:
Background. Population-specific epidemiologic data on human Papillomavirus infection, which are limited in most of the SubSaharan African countries, are necessary for effective cervical cancer prevention. This study aimed to generate population-specific data on human Papillomavirus infections, and determine which of these, self-collected and provider-collected specimens, gives a higher estimate of the prevalence of human Papillomaviruses, including vaccine and non-vaccine-type human Papillomavirus. Methods. In this cross-sectional study, following a questionnaire-based collection of epidemiological data, self-, and provider-collected specimens, obtained from women 15−65 years of age, were analysed for human Papillomavirus types by a nested-multiplex polymerase chain reaction, and for cervical lesions by Pap testing. HPV data were categorised according to risk type and vaccine types for further analysis. Results. The difference between the overall human Papillomavirus infection prevalences obtained with the self-collected specimens, 43.1% (95% CI of 38.0–51.0%) and that with the provider-collected samples, 23.3% (95% CI of 19.0–31.0%) were significant (p≤0.001). The prevalence of quadrivalent vaccine-type human Papillomaviruses was 12.3% with self-collected specimens, but 6.0% with provider-collected specimens. For the nonavalent vaccine-types, the prevalences were 26.6% and 16.7% respectively. There were multiple infections involving both vaccine-preventable and nonvaccine preventable high-risk human Papillomavirus genotypes. Conclusion. The Akuse subdistrict can, therefore, be said to have a high burden of human Papillomavirus infections, which included nonvaccine types, as detected with both self-collected and provider-collected specimens. These imply that self-collection is to be given a higher consideration as a means for a population-based high-risk human Papillomavirus infections burdens assessment/screening. Additionally, even with a successful implementation of the HPV vaccination, if introduced in Ghana, there is still the need to continue with the screening of women.
APA, Harvard, Vancouver, ISO, and other styles
5

Bősze, Péter. "The first vaccine against cancer: the human papillomavirus vaccine." Orvosi Hetilap 154, no. 16 (April 2013): 603–18. http://dx.doi.org/10.1556/oh.2013.29593.

Full text
Abstract:
The last 20 years is one of the most remarkable periods in the fight against cancer, with the realization that some human papillomaviruses are causally related to cancer and with the development of the vaccine against human papillomavirus infections. This is a historical event in medicine and the prophylactic human papillomavirus vaccines have provided powerful tools for primary prevention of cervical cancer and other human papillomavirus-associated diseases. This is very important as human papillomavirus infection is probably the most common sexually transmitted infection worldwide, and over one million women develop associated cancer yearly, which is about 5% of all female cancers, and half of them die of their disease. Cancers associated with oncogenic human papillomaviruses, mostly HPV16 and 18, include cervical cancer (100%), anal cancer (95%), vulvar cancer (40%), vaginal cancer (60%), penile cancer (40%), and oro-pharingeal cancers (65%). In addition, pre-cancers such as genital warts and the rare recurrent respiratory papillomatosis are also preventable by vaccination. Currently, the human papillomavirus vaccines have the potential to significantly reduce the burden of human papillomavirus associated conditions, including prevention of up to 70% of cervical cancers. Two prophylactic human papillomavirus vaccines are currently available worldwide: a bivalent vaccine (types 16 and 18), and a quadrivalent vaccine (types 6, 11, 16, and 18). Randomized controlled trials conducted on several continents during the last 10 years have demonstrated that these vaccines are safe without serious side effects; they are highly immunogenic and efficacious in preventing incident and persistent vaccine-type human papillomavirus infections, high grade cervical, vulvar and vaginal intraepithelial neoplasia and so on. In addition, the quadrivalent vaccine has been shown to prevent genital warts in women and men. The vaccine is most effective when given to human papillomavirus naive girls. The human papillomavirus vaccines have been incorporated into national immunization programs in 22 European countries. Routine vaccination is recommended for girls aged between 9 and 13 years and catch-up vaccination for females between 13 and 25 years of age. There is no excuse not to incorporate the vaccines into the Hungarian national immunization program. Albeit vaccination is expensive, it is cost-effective in the long run definitely. Anyway, vaccination is a matter of the specialty and the national health program, but not of business. We all are obliged to prevent human suffering. Orv. Hetil., 2013, 154, 603–618.
APA, Harvard, Vancouver, ISO, and other styles
6

Antonsson, Annika, and Bengt Göran Hansson. "Healthy Skin of Many Animal Species Harbors Papillomaviruses Which Are Closely Related to Their Human Counterparts." Journal of Virology 76, no. 24 (December 15, 2002): 12537–42. http://dx.doi.org/10.1128/jvi.76.24.12537-12542.2002.

Full text
Abstract:
ABSTRACT Papillomaviruses associated with clinical symptoms have been found in many vertebrate species. In this study, we have used an L1 gene consensus PCR test designed to detect a broad spectrum of human skin papillomaviruses to analyze swab samples from healthy skin of 111 animals belonging to 19 vertebrate species. In eight of the species, papillomavirus DNA was found with the following prevalences: chimpanzees, 9 of 11 samples positive; gorillas, 3 of 4; long-tailed macaques, 14 of 16; spider monkeys, 2 of 2; ruffed lemurs, 1 of 2; cows, 6 of 10; European elks, 4 of 4; aurochs, 1 of 1. In total, 53 new putative animal papillomavirus types were found. The results show that skin papillomaviruses can be detected in healthy skin from many different animal species and are sufficiently related genetically to their human counterparts to be identified by a human skin papillomavirus primer set (FAP59 and FAP64).
APA, Harvard, Vancouver, ISO, and other styles
7

Peh, Woei Ling, Kate Middleton, Neil Christensen, Philip Nicholls, Kiyofumi Egawa, Karl Sotlar, Janet Brandsma, et al. "Life Cycle Heterogeneity in Animal Models of Human Papillomavirus-Associated Disease." Journal of Virology 76, no. 20 (October 15, 2002): 10401–16. http://dx.doi.org/10.1128/jvi.76.20.10401-10416.2002.

Full text
Abstract:
ABSTRACT Animal papillomaviruses are widely used as models to study papillomavirus infection in humans despite differences in genome organization and tissue tropism. Here, we have investigated the extent to which animal models of papillomavirus infection resemble human disease by comparing the life cycles of 10 different papillomavirus types. Three phases in the life cycles of all viruses were apparent using antibodies that distinguish between early events, the onset of viral genome amplification, and the expression of capsid proteins. The initiation of these phases follows a highly ordered pattern that appears important for the production of virus particles. The viruses examined included canine oral papillomavirus, rabbit oral papillomavirus (ROPV), cottontail rabbit papillomavirus (CRPV), bovine papillomavirus type 1, and human papillomavirus types 1, 2, 11, and 16. Each papillomavirus type showed a distinctive gene expression pattern that could be explained in part by differences in tissue tropism, transmission route, and persistence. As the timing of life cycle events affects the accessibility of viral antigens to the immune system, the ideal model system should resemble human mucosal infection if vaccine design is to be effective. Of the model systems examined here, only ROPV had a tissue tropism and a life cycle organization that resembled those of the human mucosal types. ROPV appears most appropriate for studies of the life cycles of mucosal papillomavirus types and for the development of prophylactic vaccines. The persistence of abortive infections caused by CRPV offers advantages for the development of therapeutic vaccines.
APA, Harvard, Vancouver, ISO, and other styles
8

Alp Avci, Gulcin, and Gulendam Bozdayi. "Human Papillomavirus." Kafkas Journal of Medical Sciences 3, no. 3 (2013): 136–44. http://dx.doi.org/10.5505/kjms.2013.52724.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Richart, Ralph M., and Thomas C. Wright. "Human papillomavirus." Current Opinion in Obstetrics and Gynecology 4, no. 5 (October 1992): 662???669. http://dx.doi.org/10.1097/00001703-199210000-00003.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Fox, Paul A., and Mun-Yee Tung. "Human Papillomavirus." American Journal of Clinical Dermatology 6, no. 6 (2005): 365–81. http://dx.doi.org/10.2165/00128071-200506060-00004.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Human papillomavirus"

1

Kan, Chin-Yi. "Human Papillomavirus in human breast cancer and cellular immortalisation." Sydney : University of New South Wales. Biotechnology and Biomolecular Sciences, 2007. http://www.library.unsw.edu.au/~thesis/adt-NUN/public/adt-NUN20071004.080541/.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Brestovac, Brian. "Human papillomavirus and cervical cancer in Western Australia." University of Western Australia. School of Biomedical and Chemical Sciences, 2005. http://theses.library.uwa.edu.au/adt-WU2006.0037.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Aaltonen, Leena-Maija. "Laryngeal human Papillomavirus infection." Helsinki : University of Helsinki, 1999. http://ethesis.helsinki.fi/julkaisut/laa/haart/vk/aaltonen/.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Dareng, Eileen Onyeche. "Human papillomavirus infections and human papillomavirus associated diseases in Nigeria : distribution, determinants and control." Thesis, University of Cambridge, 2018. https://www.repository.cam.ac.uk/handle/1810/284551.

Full text
Abstract:
Background: Persistent infection with high risk HPV is a necessary but insufficient cause of cervical cancer. Behavioural, viral and host factors modulate the risk of HPV persistence. In this thesis, I explore the role of the vaginal microbiota, a host factor and the presence of multiple HPV infections, a viral factor in HPV persistence. Considering the limited data on the epidemiology of HPV related diseases in low and middle-countries (LMIC), and the limited success of cervical cancer screening strategies in many LMIC, I provide data on the distribution of HPV related diseases in Nigeria and evaluate the acceptability of innovative strategies to increase cervical cancer screening uptake. Methods/Results: To achieve my aims, I implemented a longitudinal cohort study of 1,020 women in Nigeria. I begin my results chapters with two methodological papers. Attrition is an important consideration for every longitudinal cohort, particularly in LMIC, therefore, I present my findings on attrition, determinants of attrition and practical strategies to ensure low attrition in studies conducted in LMIC. Considering that sexual behaviour is an important potential confounder in all HPV studies, and the reliability of self-reported history is often questioned, I present findings on the test-retest reliability of self-reported sexual behaviour history collected in my study. Having found that attrition levels were low and that self-reported sexual behaviour history was generally reliable within my cohort, I present my findings on the association between the vaginal microbiota and persistent hrHPV; and the role of multiple HPV infections in viral persistence. I found that the vaginal microbiota was associated with persistent hrHPV in HIV negative women, but not in HIV positive women; and that multiple HPV infections did not increase the risk of viral persistence when compared to single HPV infections. Next, I present my findings on the prevalence and incidence of anogenital warts in Nigeria, with additional reports on the prevalence of cervical cancer and other HPV associated cancers using data from two population based cancer registries. Finally, I present my findings on the acceptability of innovative strategies to improve cervical cancer screening uptake in Nigeria. I found that Nigerian women had a favorable attitude to the use of HPV DNA based screening as part of routine antenatal care, however attitudes towards the use of self-sampling techniques for HPV based cervical cancer screening varied by religious affiliations. Conclusion: In my thesis, I was able to systematically investigate the epidemiology of HPV infections in a LMIC. I considered the distribution of HPV related diseases, host and viral determinants of HPV persistence and investigated control strategies to reduce the burden of cervical cancer in a LMIC. My results provide useful data for surveillance, monitoring and evaluation of control programs on HPV and cervical cancer in Nigeria and may be useful to cervical cancer control programs in other LMIC.
APA, Harvard, Vancouver, ISO, and other styles
5

Mellin, Hanna. "Human papillomavirus in tonsillar cancer /." Stockholm : Karolinska Univ. Press, 2002. http://diss.kib.ki.se/2002/91-7349-366-X/.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Cooper, Kumarasen. "Human papillomavirus and cervical carcinogenesis." Thesis, University of Oxford, 1992. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.306091.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Dowen, Sally Elizabeth. "Human papillomavirus / host genetic interactions." Thesis, University of Cambridge, 2002. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.620590.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Dao, Luan D. "Human papillomavirus segregation and replication /." Thesis, Birmingham, Ala. : University of Alabama at Birmingham, 2008. https://www.mhsl.uab.edu/dt/2008p/dao.pdf.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Cubie, Heather A. "Human papillomavirus : pathogenesis and immunity." Thesis, University of Edinburgh, 1989. http://hdl.handle.net/1842/27846.

Full text
Abstract:
The involvement of human papilloma virus (HPV) in the aetiology and progression of cervical intraepithelial neoplasia (CIN) is still unresolved. This study was designed to assess the immunological responses to HPV types in patients presenting with varying degrees of CIN and in control groups, using in vitro measures of cellular and humoral responses. Lymphocyte proliferation assays (LPA) were performed using peripheral blood mononuclear cells (PBM) and various papillomavirus (PV) antigens. Twenty -five per cent (23/92) of patients with CIN responded to antigens derived from purified BPV, HPV -1 or HPV -2 with or without detergent disruption. The responses correlated with a past history of skin warts rather than cervical abnormalities, and the percentage of responders was similar to that in laboratory personnel (30 %) and lower than that in a group with recalcitrant common warts (50 %). Antigens specific to HPV -16 and HPV -18, in the form of bacterially expressed fusion proteins derived by the transcription and translation of the E6 and E4 open reading frames (ORF), occasionally produced specific positive responses, provided contaminating E.coli B galactosidase sequences had been removed during purification. Responses were low and suggested that the numbers of memory T cells specific to PV antigens were low and at the lower limit of detection of LPA. An indirect ELISA was developed to detect circulating IgG to PV antigens in colposcopy patients. Fifty per cent of patients had antibodies to disrupted HPV -1, HPV -2 or both, suggesting that a predominantly type- specific response was being detected. No correlation of immune responses with a degree of dysplasia or the presence of koilocytes in cervical biopsies was noted, but a high incidence of forgotten or inapparent past infection with cutaneous HPV types was found. In situ hybridisation (ISH) methods using non -radioactively labelled, cloned probes and synthetic oligonucleotide probes were developed for use on paraffin sections. Synthetic probes allowed a quicker, less destructive hybridisation protocol, with the sensitivity of detection being (y) improved by an anti -biotin -immunogold conjugated immunoglobulins -silver enhancement (IGSS) detection system. Double staining of PV antigen and nucleic acid on the same section was achieved. Synthetic oligonucleotides offer an exciting new tool for diagnostic virology, worthy of exploitation in many systems. Implantation of human foreskin infected with HPV -11 was shown to provide an animal model, albeit technically difficult, in which HPV could be produced, but a more practical technique of productive HPV infection in vitro is still required if the biology and pathogenesis of HPV infections is to be clarified further.
APA, Harvard, Vancouver, ISO, and other styles
10

Raleigh, Sarah Elizabeth. "Hispanic Parents' Knowledge, Attitudes and Beliefs Toward Human Papillomavirus and Human Papillomavirus Vaccination in Arizona." Diss., The University of Arizona, 2016. http://hdl.handle.net/10150/612848.

Full text
Abstract:
Human papillomavirus (HPV) is a sexually transmitted infection that represents a serious health issue that can lead to significant morbidity and mortality. Although FDA-approved vaccines for the prevention against the majority of strains responsible for cervical cancer and genital warts have been available for many years, immunization rates remain low. This study will consider cervical cancer as the main consequence of HPV and thus will investigate parents of daughters. This is of particular relevance to Arizona, given the large Hispanic population and the racial and ethnic disparities that exist in the incidence, mortality and survival of cervical cancer when compared to the national average. Administration of the three-dose series is recommended for girls and boys beginning at 12 years of age. The target population of this study was parents as the HPV vaccine necessitates parental consent and immunization rates remain low. This study specifically aimed to explore the knowledge, attitudes and beliefs of Hispanic parents in Maricopa County toward the HPV vaccine in efforts to identify barriers to immunization and create future implications for practice. Findings were consistent with previous literature: Hispanic parents exhibited suboptimal knowledge regarding HPV and HPV vaccination. Specific opportunities for education include the etiology, transmission and health consequences of HPV. Despite many areas for education, the majority of Hispanic parents indicated they would follow their health providers' recommendation on vaccination.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Human papillomavirus"

1

Human papillomavirus. Philadelphia: Saunders, 1987.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Rosenblatt, Alberto, and Homero Gustavo Campos Guidi. Human Papillomavirus. Berlin, Heidelberg: Springer Berlin Heidelberg, 2009. http://dx.doi.org/10.1007/978-3-540-70974-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Guilfoile, Patrick. Human papillomavirus. Edited by Babcock Hilary. New York: Chelsea House, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Richard, Reid, ed. Human papillomavirus. Philadelphia: Saunders, 1987.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

T, Lörincz Attila, and Reid Richard, eds. Human papillomavirus. Philadelphia: Saunders, 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Lorincz, Attila T. Human papillomavirus II. Philadelphia: W.B. Saunders, 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Nardo, Don. Human papillomavirus (HPV). Detroit: Lucent Books, 2007.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Jane, Sterling, and Tyring Stephen K, eds. Human papillomaviruses: Clinical and scientific advances. London: Arnold, 2001.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Tinsley, Jonathon Mark. Human papillomavirus transgenic mice. Birmingham: University of Birmingham, 1991.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Centers for Disease Control and Prevention (U.S.), ed. Genital human papillomavirus (HPV). Atlanta, Ga.]: Dept. of Health and Human Services, Centers for Disease Control and Prevention, Indian Health Service, 2011.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Human papillomavirus"

1

Reid, Gail E. "Human Papillomavirus." In The AST Handbook of Transplant Infections, 59–60. Oxford, UK: Wiley-Blackwell, 2011. http://dx.doi.org/10.1002/9781444397949.ch21.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Garland, Suzanne M. "Human Papillomavirus." In Sexually Transmitted Diseases, 85–95. Oxford, UK: Wiley-Blackwell, 2012. http://dx.doi.org/10.1002/9781118314937.ch10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Arbefeville, Sophie S., and Aaron D. Bossler. "Human Papillomavirus." In Diagnostic Molecular Pathology in Practice, 269–75. Berlin, Heidelberg: Springer Berlin Heidelberg, 2011. http://dx.doi.org/10.1007/978-3-642-19677-5_33.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Carter, James F. "Human Papillomavirus." In Encyclopedia of Women’s Health, 613–15. Boston, MA: Springer US, 2004. http://dx.doi.org/10.1007/978-0-306-48113-0_205.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Suryadevara, Manika. "Human Papillomavirus." In Vaccines, 189–98. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-58414-6_15.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Domachowske, Joseph, and Manika Suryadevara. "Human Papillomavirus." In Clinical Infectious Diseases Study Guide, 143–48. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-50873-9_23.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Patsner, Bruce, David A. Baker, and Earl Jackman. "Human Papillomavirus." In Clinical Perspectives in Obstetrics and Gynecology, 185–95. New York, NY: Springer New York, 1994. http://dx.doi.org/10.1007/978-1-4612-2640-6_10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Tabrizi, Sepehr N. "Human Papillomavirus." In PCR for Clinical Microbiology, 281–85. Dordrecht: Springer Netherlands, 2010. http://dx.doi.org/10.1007/978-90-481-9039-3_44.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Burd, Eileen M., and Christina L. Dean. "Human Papillomavirus." In Diagnostic Microbiology of the Immunocompromised Host, 177–95. Washington, DC: ASM Press, 2016. http://dx.doi.org/10.1128/9781555819040.ch8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Voytek, Theresa M., and Gregory J. Tsongalis. "Human Papillomavirus." In Molecular Diagnostics, 447–51. Totowa, NJ: Humana Press, 2006. http://dx.doi.org/10.1385/1-59259-928-1:447.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Human papillomavirus"

1

Kugelman, N., E. Siegler, L. Mackuli, O. Lavie, M. Schmidt, P. Shaked Mishan, and Y. Segev. "218 Worse Prognosis of Human Papillomavirus Negative Compared to Human Papillomavirus Positive Cervical Cancer." In ESGO 2021 Congress. BMJ Publishing Group Ltd, 2021. http://dx.doi.org/10.1136/ijgc-2021-esgo.18.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Flores, Ryan, Sahra Afshari, and Jennifer Blain Christen. "Colorimetric Point-of-Care Human Papillomavirus Diagnostic Reader." In 2019 IEEE Healthcare Innovations and Point of Care Technologies (HI-POCT). IEEE, 2019. http://dx.doi.org/10.1109/hi-poct45284.2019.8962666.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Bir, Aditya, Jyotsna Dongardive, Suruchi Jamkhedkar, and Siby Abraham. "Building consensus of Human Papillomavirus using Genetic Algorithm." In 2009 World Congress on Nature & Biologically Inspired Computing (NaBIC). IEEE, 2009. http://dx.doi.org/10.1109/nabic.2009.5393579.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Choi, J., K. Lee, W. Kim, S. Lee, H. Lim, Y. Choi, D. Kim, J. Lee, S. Nam, and J. Yang. "Human papillomavirus in breast carcinomas of Korean women." In CTRC-AACR San Antonio Breast Cancer Symposium: 2008 Abstracts. American Association for Cancer Research, 2009. http://dx.doi.org/10.1158/0008-5472.sabcs-3086.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Giaretta, A. "Human Papillomavirus Early Promoter Regulatory Core as a Bistable Switch." In 2019 41st Annual International Conference of the IEEE Engineering in Medicine & Biology Society (EMBC). IEEE, 2019. http://dx.doi.org/10.1109/embc.2019.8857023.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Wilhelm, Matthew, Brian Nutter, Rodney Long, and Sameer Antani. "Linear array image analysis for automated detection of human papillomavirus." In 2009 22nd IEEE International Symposium on Computer-Based Medical Systems (CBMS). IEEE, 2009. http://dx.doi.org/10.1109/cbms.2009.5255266.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Berenson, Abbey B., Jacqueline M. Hirth, Yong-Fang Kuo, and Richard E. Rupp. "Abstract 5285: Evaluation of a postpartum human papillomavirus vaccination program." In Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-5285.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Matsuno, Rayna K., Ben Porter, Steven Warner, Deborah B. Bookwalter, and Natalie Wells. "Abstract C055: Human papillomavirus vaccination among US military service women." In Abstracts: Eleventh AACR Conference on The Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; November 2-5, 2018; New Orleans, LA. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7755.disp18-c055.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Palefsky, Joel. "Abstract SY32-01: Human papillomavirus vaccines in females and males." In Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1538-7445.am2011-sy32-01.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Giaretta, A., and G. M. Toffolo. "Sensitivity Analysis of a Model of Human Papillomavirus Late Promoter Regulation." In 2019 41st Annual International Conference of the IEEE Engineering in Medicine & Biology Society (EMBC). IEEE, 2019. http://dx.doi.org/10.1109/embc.2019.8856475.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Human papillomavirus"

1

Clements, Adrienne M. Structural Studies of the pRB Tumor Suppressor Complexed with Human Papillomavirus E7. Fort Belvoir, VA: Defense Technical Information Center, June 1998. http://dx.doi.org/10.21236/ada354361.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Aidibai, Simayi, and Jin Hui. Association between human papillomavirus vaccination and serious adverse events in females aged 9 to 26 years: a systematic review and meta analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, February 2022. http://dx.doi.org/10.37766/inplasy2022.2.0040.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

van de Sande, Anna, Malika Kengsakul, Margot Koeneman, Marta Jozwiak, Cornelis Gerestein, Arnold-Jan Kruse, Edith van Esch, et al. Imiquimod in cervical dysplasia: a review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, November 2022. http://dx.doi.org/10.37766/inplasy2022.11.0046.

Full text
Abstract:
Review question / Objective: To determine the efficacy of topical imiquimod in treatment of high-grade CIN (defined as regression CIN 1 or less), and to determine the clearance rate of high-risk human papillomavirus (hr-HPV), compared to surgical treatment and placebo. Condition being studied: Women with an untreated, histologically proven, CIN2-3 lesion or women who were persistent high-risk HPV positive. Eligibility criteria: Studies that evaluated the efficacy of imiquimod treatment in intraepithelial lesions or malignancy of other organs, and studies published as conference abstract, narrative review, editorial, letter, or short communication were excluded.
APA, Harvard, Vancouver, ISO, and other styles
4

Wang, Huanhuan, Yuyu Zhang, Wei Bai, Bin Wang, Jinlong Wei, Ji Rui, Ying Xin, Lihua Dong, and Xin Jiang. Feasibility of immunohistochemical p16 staining in the diagnosis of human papillomavirus infection in patients with squamous cell carcinoma of the head and neck: A systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, July 2020. http://dx.doi.org/10.37766/inplasy2020.7.0068.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Li, Yanhui. Efficacy of non-invasive photodynamic therapy for female lower reproductive tract diseases associated with HPV infection: a comprehensive meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, November 2022. http://dx.doi.org/10.37766/inplasy2022.11.0092.

Full text
Abstract:
Review question / Objective: The critical point of this study was to comprehensively evaluate the curative effect of Photodynamic therapy (PDT) in diseases of female lower reproductive tract associated with the human papillomavirus (HPV) infection. Condition being studied: Traditional clinical recommendations for treating diseases of the female lower reproductive tract include topical therapy with drugs, surgery, intravaginal radiation, carbon dioxide (CO2) laser, etc. Although medication is easy to administer, it has a high recurrence rate and adverse effects such as burning sensation, pain, and dyspareunia. The other traditional treatment method is usually invasive, repeated operation of vaginal perforation, scar, easy recurrence, fertility decline, and other shortcomings. At present, the treatment strategy for cervical squamous intraepithelial lesion, vaginal squamous intraepithelial lesion, condyloma acuminatum, and vulvar lichen sclerosis are to protect the normal organ structure and function as much as possible, reduce recurrence, prevent disease progression and carcinogenesis, and preserve female reproductive function.
APA, Harvard, Vancouver, ISO, and other styles
6

Gidengil, Courtney, Matthew Bidwell Goetz, Margaret Maglione, Sydne J. Newberry, Peggy Chen, Kelsey O’Hollaren, Nabeel Qureshi, et al. Safety of Vaccines Used for Routine Immunization in the United States: An Update. Agency for Healthcare Research and Quality (AHRQ), May 2021. http://dx.doi.org/10.23970/ahrqepccer244.

Full text
Abstract:
Objective. To conduct a systematic review of the literature on the safety of vaccines recommended for routine immunization in the United States, updating the 2014 Agency for Healthcare Research and Quality (AHRQ) report on the topic. Data sources. We searched MEDLINE®, Embase®, CINAHL®, Cochrane CENTRAL, Web of Science, and Scopus through November 9, 2020, building on the prior 2014 report; reviewed existing reviews, trial registries, and supplemental material submitted to AHRQ; and consulted with experts. Review methods. This report addressed three Key Questions (KQs) on the safety of vaccines currently in use in the United States and included in the Centers for Disease Control and Prevention’s (CDC) recommended immunization schedules for adults (KQ1), children and adolescents (KQ2), and pregnant women (KQ3). The systematic review was supported by a Technical Expert Panel that identified key adverse events of particular concern. Two reviewers independently screened publications; data were extracted by an experienced subject matter expert. Studies of vaccines that used a comparator and reported the presence or absence of adverse events were eligible. We documented observed rates and assessed the relative risks for key adverse events. We assessed the strength of evidence (SoE) across the existing findings from the prior 2014 report and the new evidence from this update. The systematic review is registered in PROSPERO (CRD42020180089). Results. A large body of evidence is available to evaluate adverse events following vaccination. Of 56,608 reviewed citations, 189 studies met inclusion criteria for this update, adding to data in the prior 2014 report, for a total of 338 included studies reported in 518 publications. Regarding vaccines recommended for adults (KQ1), we found either no new evidence of increased risk for key adverse events with varied SoE or insufficient evidence in this update, including for newer vaccines such as recombinant influenza vaccine, adjuvanted inactivated influenza vaccine, and recombinant adjuvanted zoster vaccine. The prior 2014 report noted a signal for anaphylaxis for hepatitis B vaccines in adults with yeast allergy and for tetanus, diphtheria, and acellular pertussis vaccines. Regarding vaccines recommended for children and adolescents (KQ2), we found either no new evidence of increased risk for key adverse events with varied SoE or insufficient evidence, including for newer vaccines such as 9-valent human papillomavirus vaccine and meningococcal B vaccine. The prior 2014 report noted signals for rare adverse events—such as anaphylaxis, idiopathic thrombocytopenic purpura, and febrile seizures—with some childhood vaccines. Regarding vaccines recommended for pregnant women (KQ3), we found no evidence of increased risk for key adverse events with varied SoE among either pregnant women or their infants following administration of tetanus, diphtheria, and acellular pertussis vaccines during pregnancy. Conclusion. Across this large body of research, we found no new evidence of increased risk since the prior 2014 report for key adverse events following administration of vaccines that are routinely recommended. Signals from the prior report remain unchanged for rare adverse events, which include anaphylaxis in adults and children, and febrile seizures and idiopathic thrombocytopenic purpura in children. There is no evidence of increased risk of adverse events for vaccines currently recommended in pregnant women. There remains insufficient evidence to draw conclusions about some rare potential adverse events.
APA, Harvard, Vancouver, ISO, and other styles
7

CIOMS Guide to Active Vaccine Safety Surveillance. Council for International Organizations of Medical Sciences (CIOMS), 2017. http://dx.doi.org/10.56759/hnuw8440.

Full text
Abstract:
With more vaccine solutions available and opportunities for earlier availability of new vaccine products in resource-limited countries (e.g. vaccines against rotavirus, human papillomavirus or pneumococci) as well as new products that address diseases endemic in those countries only (e.g. malaria, dengue among others), generating reliable data about specific safety concerns is becoming a priority for all countries. The Guide offers a practical step-by-step approach and algorithm to aid immunization professionals and decision-makers in determining the best course of action if additional vaccine safety data is needed. The Guide provides a structured process for evaluating whether significant knowledge gaps exist, whether passive safety surveillance is adequate, and if not, methods for and practical aspects of conducting active vaccine safety surveillance. The Guide also includes an essential vaccine information source list for evaluating the extent of data resources and several case studies for review. This CIOMS publication more than any other in recent history focuses on the special needs of the country level organizations responsible for developing vaccines safety surveillance strategies and implementing new vaccination programmes into resource-limited environments.
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Human papillomavirus' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography